Nicox SA (OTCMKTS:NICXF – Free Report) – Equities research analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for Nicox in a research note issued to investors on Wednesday, December 17th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.18 per share for the quarter, up from their previous forecast of $0.17. HC Wainwright currently has a “Buy” rating on the stock.
Separately, Zacks Research upgraded Nicox to a “hold” rating in a research report on Friday, October 10th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.
Nicox Price Performance
NICXF stock opened at $0.30 on Thursday. The company has a fifty day moving average price of $0.30 and a 200-day moving average price of $0.29. Nicox has a 52-week low of $0.25 and a 52-week high of $0.30.
Nicox Company Profile
Nicox SA operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.
Read More
- Five stocks we like better than Nicox
- How to Find Undervalued Stocks
- Rate Cuts Make These 3 Income ETFs More Attractive Than Ever
- Comparing and Trading High PE Ratio Stocks
- Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport
- The 3 Best Blue-Chip Stocks to Buy Now
- Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock
Receive News & Ratings for Nicox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nicox and related companies with MarketBeat.com's FREE daily email newsletter.
